MAP2K7 and breast cancer: Intriguingly, application of the PPARγ agonist rosiglitazone in combination with the MEK inhibitor trametinib can terminally differentiate breast cancer cells that have undergone epithelial-mesenchymal transition (EMT) into adipocytes [57].